Results 41 to 50 of about 218,137 (295)

PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells [PDF]

, 2018
CD4+ T cell differentiation into multiple T helper (Th) cell lineages is critical for optimal adaptive immune responses. This report identifies an intrinsic mechanism by which programmed death-1 receptor (PD-1) signaling imparted regulatory phenotype to ...
Amarnath, Shoba, Berlinguer-Palmini, Rolando, Bogyo, Matthew, Eckhaus, Michael A., Edgington-Mitchell, Laura, Felizardo, Tania C., Flomerfelt, Francis A., Fowler, Daniel H., Gangaplara, Arunakumar, Knight, David, Laurence, Arian, Liniany, Lukasz P., Mallett, Grace, Martinez-Fabregas, Jonathan, Samsel, Leigh A., Shevach, Ethan M., Stathopoulou, Chaido, van Kasteren, Sander I., Watts, Colin, Yim, Joshua J., Zhu, Jinfang   +20 more
core   +2 more sources

Anti program death-1/anti program death-ligand 1 in digestive cancers

World Journal of Gastrointestinal Oncology, 2015
Human tumors tend to activate the immune system regulatory checkpoints as a means of escaping immunosurveillance. For instance, interaction between program death-1 (PD-1) and program death-ligand 1 (PD-L1) will lead the activated T cell to a state of anergy. PD-L1 is upregulated on a wide range of cancer cells.
Eléonore, de Guillebon, Pauline, Roussille, Eric, Frouin, David, Tougeron   +3 more
openaire   +2 more sources

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Polish Journal of Pathology, 2021
Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin, Emine Bagir, Merve Inceman, Mutlu Deger, Seyda Erdogan   +4 more
doaj   +1 more source

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy [PDF]

Journal of Clinical Oncology, 2017
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte ...
Jarushka, Naidoo, Xuan, Wang, Kaitlin M, Woo, Tunc, Iyriboz, Darragh, Halpenny, Jane, Cunningham, Jamie E, Chaft, Neil H, Segal, Margaret K, Callahan, Alexander M, Lesokhin, Jonathan, Rosenberg, Martin H, Voss, Charles M, Rudin, Hira, Rizvi, Xue, Hou, Katherine, Rodriguez, Melanie, Albano, Ruth-Ann, Gordon, Charles, Leduc, Natasha, Rekhtman, Bianca, Harris, Alexander M, Menzies, Alexander D, Guminski, Matteo S, Carlino, Benjamin Y, Kong, Jedd D, Wolchok, Michael A, Postow, Georgina V, Long, Matthew D, Hellmann   +28 more
openaire   +2 more sources

Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report

BMC Pulmonary Medicine, 2021
Background Immune checkpoint inhibitors have potential applications in treating various cancers but are associated with immune-related adverse events, such as inflammation, in a wide range of organs; however, allergic inflammation caused by these agents ...
Masanori Harada, Hyogo Naoi, Kazuyo Yasuda, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Masaru Tsukui, Naoki Koshimizu   +11 more
doaj   +1 more source

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis [PDF]

, 2014
INTRODUCTION: A major pathophysiologic mechanism in sepsis is impaired host immunity which results in failure to eradicate invading pathogens and increased susceptibility to secondary infections.
Andriani C Patera, Bryan Sato, Catherine Svabek, Cristina Vazquez-Guillamet, David Rasche, JoAnn Suzich, Jonathan Green, Katherine Chang, Nancy Ulbrandt, Paul Robbins, Richard Hotchkiss, Strother Wilson, Subramaniam Krishnan, Wade Blair   +13 more
core   +2 more sources

Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer

Zhongliu Fangzhi Yanjiu, 2023
Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS.
DENG Changgang, ZHANG Wei, SUN Yanyu, LI Qisui, HUANG Wei, YUAN Jing   +5 more
doaj   +1 more source

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab [PDF]

, 2016
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration.
Caponnetto, Salvatore, Cortesi, Enrico, DEL BENE, Gabriella, Gandini, Orietta, Gazzaniga, Paola, Gradilone, Angela, Longo, F, Mancini, Marialaura, Mastromartino, M, Nicolazzo, Chiara, Prete, ALESSANDRA ANNA, Raimondi, Cristina   +11 more
core   +1 more source

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer [PDF]

, 2017
Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable.
Babu, Sunil, Kiel, Patrick J., Kollipara, Revathi, Radovich, Milan, Schneider, Bryan   +4 more
core   +1 more source

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity

Cells, 2022
Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality.
Paulina Niedźwiedzka-Rystwej, Adam Majchrzak, Bogusz Aksak-Wąs, Karol Serwin, Zenon Czajkowski, Ewelina Grywalska, Izabela Korona-Głowniak, Jacek Roliński, Miłosz Parczewski   +8 more
doaj   +1 more source